What To Expect From GW Pharma's Upcoming Round Of Presentations

The American Epilepsy Society (AES) annual meeting is scheduled to be held between December 2 and 6, during which GW Pharmaceuticals PLC-ADR GWPH will present on its lead anti-epilepsy drug Epidiolex, providing data from the first two positive Phase 3 studies.

What To Expect

The presentations will likely focus on “the Ph3 primary endpoint (reduction in seizure frequency) as well as secondary endpoints,” Goldman Sachs’ Salveen Richter said in a report. He maintains a Buy rating on the company, with a price target of $185.

GW Pharma is unlikely to present drug-drug interaction (DDI) data related to concomitant anti-epileptics including clobazam, Richter mentioned.

“At AES, we expect to see key secondary endpoint data for the first time, including a responder analysis and safety,” the analyst said. He added that while in the past the EMA (European Medicines Agency) had focused on a 50 percent responder rate, it may accept a 40–50 percent range.

The U.S. market contributes 77 percent to the peak sales estimate of $1.6 billion in 2025. “In our view, the breadth of data to date from the three positive Ph3 top-line reports and the EAP support approval,” Richter commented.

“Data to date supports Epidiolex activity, irrespective of concomitant clobizam use,” the analyst added.

At last check, GW Pharma was up 0.77 percent at $119.58.